Cargando…
Avelumab, an anti-PD-L1 antibody, in patients with locally advanced or metastatic breast cancer: a phase 1b JAVELIN Solid Tumor study
PURPOSE: Agents targeting programmed death receptor 1 (PD-1) or its ligand (PD-L1) have shown antitumor activity in the treatment of metastatic breast cancer (MBC). The aim of this study was to assess the activity of avelumab, a PD-L1 inhibitor, in patients with MBC. METHODS: In a phase 1 trial (JAV...
Autores principales: | Dirix, Luc Y., Takacs, Istvan, Jerusalem, Guy, Nikolinakos, Petros, Arkenau, Hendrik-Tobias, Forero-Torres, Andres, Boccia, Ralph, Lippman, Marc E., Somer, Robert, Smakal, Martin, Emens, Leisha A., Hrinczenko, Borys, Edenfield, William, Gurtler, Jayne, von Heydebreck, Anja, Grote, Hans Juergen, Chin, Kevin, Hamilton, Erika P. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer US
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5807460/ https://www.ncbi.nlm.nih.gov/pubmed/29063313 http://dx.doi.org/10.1007/s10549-017-4537-5 |
Ejemplares similares
-
Long-term avelumab in advanced non-small-cell lung cancer: summaries and post hoc analyses from JAVELIN Solid Tumor
por: Hrinczenko, Borys, et al.
Publicado: (2022) -
Pharmacometric modeling and machine learning analyses of prognostic and predictive factors in the JAVELIN Gastric 100 phase III trial of avelumab
por: Terranova, Nadia, et al.
Publicado: (2022) -
Avelumab in patients with previously treated metastatic adrenocortical carcinoma: phase 1b results from the JAVELIN solid tumor trial
por: Le Tourneau, Christophe, et al.
Publicado: (2018) -
Avelumab in patients with previously treated metastatic melanoma: phase 1b results from the JAVELIN Solid Tumor trial
por: Keilholz, Ulrich, et al.
Publicado: (2019) -
Efficacy and safety of first-line avelumab in patients with advanced non-small cell lung cancer: results from a phase Ib cohort of the JAVELIN Solid Tumor study
por: Verschraegen, Claire F, et al.
Publicado: (2020)